Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer

Journal of Cancer Research and Clinical Oncology
David Aguiar BujandaJosé Aguiar Morales

Abstract

To assess the efficacy and the toxicity of a new combination of epirubicin, cyclophosphamide and paclitaxel as neoadjuvant chemotherapy for breast cancer. Patients with stage II and III breast cancer received 3-4 cycles of epirubicin 75 mg/m(2) plus cyclophosphamide 600 mg/m(2) on day 1, and paclitaxel at a dose of 100 mg on days 1, 8, 15 and 22 on a 28-day cycle. Forty-nine patients were enrolled in the study. Stage II was present in 16 patients (32.7%) and stage III in 33 patients (67.3%). Relevant toxicities were nausea/vomiting grades III-IV in 6 patients (12.2%) and neutropenia grade III-IV in 33 patients (67.3%). The overall clinical response rate was 83.7%. Partial response was observed in 25 patients (51%), complete response in 16 patients (32.7%), stable disease in 7 patients (14.3%) and progression in 1 patient. Thirty-three non-inflammatory breast cancer patients underwent surgery, 29 with breast-conserving surgery (87.9%). Pathological complete response was found in 5 patients (15.1%). The combination of epirubicin, cyclophosphamide and weekly paclitaxel as given in this study is safe and shows good activity in the neoadjuvant setting of stage II and III breast cancer patients.

References

Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G BonadonnaM Zambetti
Apr 16, 1998·American Journal of Clinical Oncology·J P FerrièreP Chollet
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B FisherH D Bear
Mar 18, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KuererS E Singletary
Sep 29, 1999·Cancer Chemotherapy and Pharmacology·L G WangD R Budman
Nov 5, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A U BuzdarG N Hortobagyi
Jun 13, 2000·Cancer Biotherapy & Radiopharmaceuticals·D H LauA T Cheung
Oct 12, 2000·Nihon rinsho. Japanese journal of clinical medicine·Y Takatsuka
Nov 16, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J A van der HageL Duchateau
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ian C SmithKeith N Ogston
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Eva SingletaryFrederick L Greene
Nov 1, 2002·Breast Cancer Research and Treatment·Hervé CuréPhilippe Chollet
Oct 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Harry D BearUNKNOWN National Surgical Adjuvant Breast and Bowel Project Protocol B-27
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Véronique DiérasPierre Pouillart
Apr 2, 2005·Breast Cancer Research and Treatment·Steven D HeysAndrew W Hutcheon
Apr 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T R Jeffry EvansJanine L Mansi
Aug 10, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marjorie C GreenGabriel N Hortobagyi

❮ Previous
Next ❯

Citations

Oct 3, 2014·Chemotherapy Research and Practice·Hamid Reza MirzaeiParastoo Hajian
Nov 1, 2006·Expert Opinion on Drug Discovery·Janos Nadas, Duxin Sun
Oct 22, 2011·Clinical Oncology : a Journal of the Royal College of Radiologists·S GuptaR A Badwe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.